Fig. 7

MiR-31-5p targeted TRAF6 by binding to its 3’-UTR region. a The relative expression of miR-31-5p with mimic transfection in the neuron 2a cells was determined by qRT-PCR. ^** P < 0.01 vs. scramble. Two-tailed unpaired t-test, n = 3. b, c Western blotting analysis of TRAF6 in the neuron 2a cells with miR-31-5p mimic transfection. ^** P < 0.01 vs. scramble. Two- tailed unpaired t-test, n = 3. d Relative expression of miR-31-5p with inhibitor transfection in the neuron 2a cells was determined by qRT-PCR. ^** P < 0.01 vs. scramble. Two-tailed unpaired t-test, n = 3. e, f Western blotting analysis of TRAF6 in the neuron 2a cells with miR-31-5p inhibitor transfection. ^* P < 0.05 vs. scramble. Two- tailed unpaired t-test, n = 3. g, h Western blotting analysis of TRAF6 protein expression in the DRG of naive mice on day 3 after treated with intrathecal miR-31-5p inhibitors. ^**P < 0.01 vs. naive; two-way ANOVA, n = 3. i, j Western blot analysis of TRAF6 protein expression in the DRG of CCI mice at 14 days injected with intrathecal miR-31-5p mimic. ^** P < 0.01 vs. naive; ^## P < 0.01 vs. CCI + NS. two-way ANOVA, n = 3. k TRAF6 promoter luciferase reporter (TRAF6-Luc) was co-transfected with miR-31-5p mimic in 293T cells for 24 h, and then relative luciferase activity was analyzed. ^** P < 0.01 vs. naïve, ^# P < 0.05 vs. previous group, ^{# #}P < 0.01 vs. previous group. one -way ANOVA